Trials / Terminated
TerminatedNCT03502954
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039
A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Affibody · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-039 after single and multiple doses in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABY-039 | ABY-039 |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2018-02-26
- Primary completion
- 2020-02-01
- Completion
- 2020-03-20
- First posted
- 2018-04-19
- Last updated
- 2020-06-17
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03502954. Inclusion in this directory is not an endorsement.